NA
SAGE

Neuburgh Advisers’s Sage Therapeutics SAGE Stock Holding History

Neuburgh Advisers’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		$349K Hold
2,486
– – 0.01% 551
2019
Q2 		$455K Buy
2,486
+110
+5% +$18.8K 0.01% 487
2019
Q1 		$378K Buy
2,376
+308
+15% +$44.6K 0.01% 522
2018
Q4 		$198K Sell
2,068
-132
-6% -$15.1K 0.01% 637
2018
Q3 		$311K Buy
2,200
+1,760
+400% +$272K 0.01% 609
2018
Q2 		$69K Buy
440
+418
+1,900% +$65.6K ﹤0.01% 823
2018
Q1 		$4K Buy
+22
New +$3.73K ﹤0.01% 893

Other funds holding SAGE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Neuburgh Advisers's SAGE Position: Q3 2019 in Review

Neuburgh Advisers held its Sage Therapeutics (SAGE) position steady in Q3 2019 at 2,486 shares worth $349K. The position accounts for 0.01% of the portfolio, ranked #551.

Neuburgh Advisers first reported a position in SAGE in Q1 2018 and has held it in 7 quarters since. The position peaked at $455K in Q2 2019. 284 funds tracked by Wall St. Rank hold SAGE as of Q3 2019.

  • Neuburgh Advisers held 2,486 shares of Sage Therapeutics worth $349K as of Q3 2019.
  • Neuburgh Advisers left its Sage Therapeutics share count unchanged in Q3 2019.
  • Sage Therapeutics made up 0.01% of Neuburgh Advisers's portfolio in Q3 2019, its #551 holding.
  • Neuburgh Advisers first reported a position in Sage Therapeutics in Q1 2018 and has held it in 7 quarters since.
  • Neuburgh Advisers's Sage Therapeutics position peaked at $455K in Q2 2019.
  • 284 funds tracked by Wall St. Rank held Sage Therapeutics as of Q3 2019.

Based on Neuburgh Advisers's 13F filing for Q3 2019, filed 14 Nov 2019.